Novartis Investigative Site

Harderwijk 3840 AC

0 studies enrolling now · 8 studies all time

What they study most

Asthma, Chronic Heart Failure With Reduced Ejection Fraction, Chronic Obstructive Pulmonary Disease, Heart Failure With Preserved Ejection Fraction, Non-Small Cell Lung Cancer, Pulmonary Disease, Chronic Obstructive

Studies at this site

• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients — Completed
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer — Stopped early
• Dose Finding Study for QAW039 in Asthma — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma — Stopped early
• Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo — Completed